Q: GUD. The stock seems stuck at 10.50$.
Would you advise simply resilience, and awaiting the outcome ?
Would you advise simply resilience, and awaiting the outcome ?
You can view 3 more answers this month. Sign up for a free trial for unlimited access.
Investment Q&A
Not investment advice or solicitation to buy/sell securities. Do your own due diligence and/or consult an advisor.
Q: In your last answer on crh do you take into account the correction issued by the company regarding its first press release ?
Q: Which of these two, At current prices, would you buy today, assuming one has a balanced portfolio?
Thx
Karim
Thx
Karim
Q: Do you know if the secondary offering of PKI shares has closed? There is no confirmation on SEDAR and my broker (RBC Direct) hasn't participated in this (yet).
If it has closed, with the price holding above $29, would you consider this a good time to add?
If it has closed, with the price holding above $29, would you consider this a good time to add?
Q: With the recent drop in price,would this be a good time to take a position for growth?
Q: CRH down another ten percent today. Can you please comment on this after the CC. Do you still recommend holding this.
Q: Good morning and thank you for all your wisdom
Wondering about MX would you beable to shed any light on the drop today
Wondering about MX would you beable to shed any light on the drop today
Q: Sorry, another CRH question. The stock is down after what looked like a solid earning quarter. is there something in the earnings report that investors do not like? Your thought on the continued selling pressure.
Q: Hello,
What about Methenex's results did the market not like?
Regards,
Robert
What about Methenex's results did the market not like?
Regards,
Robert
Q: Rrx, Tog and Spe, which one would you prefer better? Thank you.
Q: I purchased some of this stock for an RESP about a year ago. It has climbed nicely. The company seemingly achieved a good measure of success before going public. What are your views of this company and the stock going forward?
Q: I know you commented on DBO on Monday, but the share price has dropped another 10% since then.The share price has been dropping for almost a year now. I was considering giving it another quarter but I feel mgmt is taking the company in the wrong direction with the talk about moving into the Motion Industrial training market, which is very niche. That and the numbers continue to disappoint every quarter. Is it time to let DBO go? Earnings are mid June.
Q: Good morning 5i team,
Plz comment on quarter.
Thanks,
Dave
Plz comment on quarter.
Thanks,
Dave
Q: Hi,
I currently hold half positions in GUD and PHO. I would like to top one of them up to a full position. Which of these 2 companies do you think would be best to top up? Or do you think both should be topped up?
Thanks for all of your great advice.
Rob
I currently hold half positions in GUD and PHO. I would like to top one of them up to a full position. Which of these 2 companies do you think would be best to top up? Or do you think both should be topped up?
Thanks for all of your great advice.
Rob
Q: Sorry another comment that Members owning CRH may find comforting and certainly shows the clear difference between it and Valeant/Concordia:
"At March 31, 2017 , the Company had $9,232,240 in cash and cash equivalents compared to $9,507,004 at the end of 2016. The decrease in cash and equivalents is primarily a reflection of cash generated from operations, less cash used to finance acquisitions during the first quarter of 2017"
Looking at the Cash Flow Statement: they generated CF-Op of $8M and acquisition cost was $7.5M. Net Debt did go up ~$3M to fund some distribution to non-controlling interest (need to dig more into note 4 for details).
The main point through is CRH earns real cash and finances its acquisitions mainly from its cash flow and not from out of control debt - as the Motley Fool article was suggesting.
"At March 31, 2017 , the Company had $9,232,240 in cash and cash equivalents compared to $9,507,004 at the end of 2016. The decrease in cash and equivalents is primarily a reflection of cash generated from operations, less cash used to finance acquisitions during the first quarter of 2017"
Looking at the Cash Flow Statement: they generated CF-Op of $8M and acquisition cost was $7.5M. Net Debt did go up ~$3M to fund some distribution to non-controlling interest (need to dig more into note 4 for details).
The main point through is CRH earns real cash and finances its acquisitions mainly from its cash flow and not from out of control debt - as the Motley Fool article was suggesting.
Q: Your analysis and thoughts on CRH's quarterly results?
Thanks!
Thanks!
Q: You mentioned CRH Management will hopefully address the short report in their Management call tomorrow. They already took a first jab in the quarterly release:
"While acquiring less than 100% of an anesthesia business will obviously create more rapid increases to non-controlling interests versus purchasing the entire business, our joint venture strategy does significantly increase our opportunities for accretive acquisitions. As a result, our acquisition pipeline remains strong and we are confident in our ability to deliver on our growth strategy."
"While acquiring less than 100% of an anesthesia business will obviously create more rapid increases to non-controlling interests versus purchasing the entire business, our joint venture strategy does significantly increase our opportunities for accretive acquisitions. As a result, our acquisition pipeline remains strong and we are confident in our ability to deliver on our growth strategy."
Q: Please comment on MX results. Thanks
Q: it looks like crh beat earnings and revenue big time, your take. dave
Q: Should be interesting, can you comment on the earnings when they come out. Thx